ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,860.00
0.49%
S&P ASX All Technology
3,102.60
0.47%
Brent Oil
79.395
0.00%
US Dollar vs AUD
1.51653
-0.06%
Bitcoin
69,437.00
0.15%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Evoke Pharma Inc (EVOK)

  7. Evoke Pharma Inc (EVOK) News

EVOK

Evoke Pharma (EVOK)

Evoke Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EVOK
DateTimeSourceHeadlineSymbolCompany
07/06/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVOKEvoke Pharma Inc
31/05/202408:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EVOKEvoke Pharma Inc
25/05/202407:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVOKEvoke Pharma Inc
25/05/202406:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVOKEvoke Pharma Inc
25/05/202406:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVOKEvoke Pharma Inc
17/05/202406:02GlobeNewswire Inc.Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) ConferenceNASDAQ:EVOKEvoke Pharma Inc
15/05/202406:58Edgar (US Regulatory)Form ARS/A - Annual Report to Security Holders: [Amend]NASDAQ:EVOKEvoke Pharma Inc
15/05/202406:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVOKEvoke Pharma Inc
15/05/202406:15GlobeNewswire Inc.Evoke Pharma Reports First Quarter 2024 Financial ResultsNASDAQ:EVOKEvoke Pharma Inc
15/05/202406:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVOKEvoke Pharma Inc
15/05/202406:05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:EVOKEvoke Pharma Inc
15/05/202406:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVOKEvoke Pharma Inc
17/04/202422:30GlobeNewswire Inc.Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsNASDAQ:EVOKEvoke Pharma Inc
22/03/202407:15GlobeNewswire Inc.Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive OfficerNASDAQ:EVOKEvoke Pharma Inc
15/03/202407:05GlobeNewswire Inc.Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:EVOKEvoke Pharma Inc
08/03/202408:10GlobeNewswire Inc.Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024NASDAQ:EVOKEvoke Pharma Inc
24/02/202408:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVOKEvoke Pharma Inc
21/02/202408:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EVOKEvoke Pharma Inc
15/02/202401:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVOKEvoke Pharma Inc
14/02/202423:30GlobeNewswire Inc.Evoke Pharma Announces Closing of $7.5 Million Public OfferingNASDAQ:EVOKEvoke Pharma Inc
10/02/202409:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVOKEvoke Pharma Inc
10/02/202409:14Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:EVOKEvoke Pharma Inc
09/02/202423:30GlobeNewswire Inc.Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 MillionNASDAQ:EVOKEvoke Pharma Inc
09/02/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVOKEvoke Pharma Inc
08/02/202422:50Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:EVOKEvoke Pharma Inc
11/01/202413:38Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:EVOKEvoke Pharma Inc
05/01/202408:30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:EVOKEvoke Pharma Inc
20/12/202300:30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:EVOKEvoke Pharma Inc
16/12/202308:30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:EVOKEvoke Pharma Inc
30/11/202301:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVOKEvoke Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:EVOK

Your Recent History

FX
AUDJPY
AUD vs Yen
COIN
ETHUSD
Ethereum
FX
AUDCAD
AUD vs CAD
NASDAQ
NVDA
NVIDIA
ASX
AMP
AMP
NYSE
XOM
Exxon Mobil
ASX
XJO
S&P ASX 200
ASX
SUN
Suncorp
NASDAQ
TSLA
Tesla
SPI
SP500
S&P 500
ASX
MQG
Macquarie
ASX
XTO
S&P ASX 100
FX
GBPAUD
Sterling vs AUD
ASX
WDC
Westfield
ASX
XMM
S&P ASX 300 Metals and M...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved